Althea Group Ventures

About The Fund

Althea Group Ventures is an early-stage investment firm that specializes in providing growth capital and strategic advisory services. They focus on companies that are innovating across various sectors such as BioTech, Business Solutions, FinTech and Financial Services, IoT and Wearables, A.I. and Big Data, HealthTech and Fitness, Medical Devices and Hospital Services, DeepTech, and Healthcare and Wellness. With an investment range from $100,000 to a maximum of $5,000,000, their sweet spot for investment lies around $1,500,000. Althea Group Ventures actively searches for innovative firms at the Seed, Series A, and Series B stages. They have a track record that includes developing next-generation genetic medicines featuring safe, effective, and redosable nucleic acid delivery technologies. Their investments also showcase a revolutionary approach to combating diseases such as COVID-19 with breakthrough Fusogenix gene delivery technology. Other notable investments include next-generation cancer therapy targeting P53, intellectual property management software catering to automated trademark docketing, IoT-enabled trackers for women's reproductive health, solutions for individual digestive health utilizing data and AI, biofeedback tech for telehealth, and novel tests for Endometriosis. Additionally, they highlight an exit with Inmar Intelligence's acquisition of RxTransparent, a company which developed innovative solutions in the pharmaceutical space. These investments reflect the firm's commitment to fostering transformational changes in health and technology infrastructures. Althea Group Ventures is also involved in continuing the lifecycle of investments from Seed to Exit, indicating their long-term commitment to the successful scaling and developing of the ventures they engage with. They offer more than just capital by providing significant expertise and advisory to support the growth and scaling of their portfolio companies.